2024

when

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">Johnson &amp; Johnson (NYSE: JNJ) reported a robust performance in the <a href="https://www.businesswire.com/news/home/20241014447723/en/Johnson-Johnson-Reports-Q3-2024-Results" target="_blank" aria-label="third quarter of 2024 (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">third quarter of 2024</a>, demonstrating a 5.2% increase in reported sales, reaching $22.5 billion. The operational growth was slightly higher at 6.3%, showcasing the company’s resilience and adaptability in a competitive market.</p>
<p>This growth was driven by strategic advancements in both the Innovative Medicine and MedTech segments. In particular, the MedTech segment saw a 5.8% increase in reported sales, bolstered by the performance of electrophysiology products and the launch of new technologies such as the VELYS Spine and Shockwave E IVL Catheter. <br><br>The Innovative Medicine segment also contributed significantly, with worldwide operational sales growing by 6.3%. This growth was largely fueled by the success of products like DARZALEX in the oncology sector and TREMFYA in immunology.</p>
<p>However, the segment faced some challenges, with products like STELARA and SIMPONI experiencing a decline in sales. Despite these hurdles, the segment’s performance underscores Johnson &amp; Johnson’s commitment to delivering innovative healthcare solutions. <br><br><a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="noopener noreferrer nofollow" class="deco-link">Earnings per share (EPS)</a> for the quarter were reported at $1.11, a decrease of 34.3% from the previous year, primarily due to one-time special charges and acquired in-process research and development (IPR&amp;D) expenses.</p>
<p>On an adjusted basis, EPS was $2.42, marking a 9.0% decline. The company’s free cash flow year-to-date stood at approximately $14 billion, reflecting strong cash generation capabilities despite the challenges faced.</p>
<h3 id="johnson-johnson-reports-double-beat-in-third-quarter">Johnson &amp; Johnson Reports Double Beat in Third Quarter</h3>
<p>Johnson &amp; Johnson’s third-quarter performance, while strong in several areas, fell short of market expectations. Analysts had anticipated an EPS of $2.19 and revenue of $22.17 billion. The reported EPS of $1.11 was significantly below expectations, largely due to the aforementioned special charges and IPR&amp;D expenses.</p>
<p>However, the adjusted EPS of $2.42 exceeded expectations, indicating robust underlying business performance when excluding these one-time items. Revenue, on the other hand, surpassed expectations, coming in at $22.5 billion compared to the anticipated $22.17 billion. This revenue beat was driven by solid sales in both the U.S. and international markets.</p>
<p>In the U.S., sales grew by 7.6%, reflecting strong demand for the company’s innovative products. International sales also saw a modest increase, despite facing headwinds from currency fluctuations.The company’s performance in the MedTech segment was particularly noteworthy, with operational sales growth of 6.4%, exceeding the expectations set for this segment.</p>
<p>This growth was supported by strategic acquisitions and the successful integration of new technologies, which helped offset declines in other areas. Overall, while the EPS fell short of expectations, the revenue beat and segmental growth highlight Johnson &amp; Johnson’s robust operational capabilities.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="johnson-johnson-revises-full-year-guidance-expects-9-91-adjusted-operational-eps">Johnson &amp; Johnson Revises Full Year Guidance, Expects $9.91 Adjusted Operational EPS</h3>
<p>Looking ahead, Johnson &amp; Johnson has updated its full-year 2024 guidance, reflecting both improved performance and the impact of recent acquisitions. The company now expects adjusted operational EPS to be around $9.91, down from the previous guidance of $10.05. This revision accounts for the costs associated with the acquisition of V-Wave, which more than offset the performance improvements observed during the quarter.</p>
<p>The company’s operational sales guidance has been adjusted to a range of $89.4 billion to $89.8 billion, with a midpoint of $89.6 billion. This reflects an expected growth rate of 6.3% to 6.8% compared to the prior year.<br><br>Johnson &amp; Johnson’s leadership remains optimistic about the company’s long-term growth prospects, driven by its strong pipeline and strategic investments in innovative healthcare solutions.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/johnson-johnsons-medtech-segment-shines-with-exceeding-sales-growth-in-q3/">Johnson &amp; Johnson’s MedTech Segment Shines with Impressive Q3 Growth</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Johnson & Johnson’s MedTech Segment Shines with Impressive Q3 Growth

Table of Contents

Tokenist

Other articles published on Oct 15, 2024

Surging Ethereum Open Interest Hits 5-Month Peak: Implications for ETH Explained

What Will The Future Of Crypto Look Like If Harris Wins? Analysts Discuss Implications For XRP, E...

Maximum Tensions Between China And Taiwan: Towards An Inevitable War?

Ripple backs $25m round for crypto platform Bitnomial

Trump Satoshi (TRUMPSAT) Will Explode Over 14,000% Before Exchange Listings, While Shiba Inu and ...

JASMY and FLOKI Indicate Major Pump Signs of 1,200% and 255% Respectively, Which Will Surge First?

Join our free newsletter for daily crypto updates!